Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877465 | 0.75 | DPP4 (0.40) | DPP4DPP7BPTF | |
| SCHEMBL2869935 | 0.69 | POLB (0.54) | DPP4DPP7BPTFHSD11B1GRIN2B | |
| SCHEMBL14305080 | 0.67 | DPP4 (0.45) | DPP4DPP7HSD11B1GRIN2BNAMPT | |
| SCHEMBL16215801 | 0.64 | DPP4 (0.41) | DPP4DPP7HSD11B1GRIN2BNAMPT | |
| SCHEMBL1347525 | 0.64 | DPP4 (0.41) | DPP4DPP7HSD11B1GRIN2BNAMPT | |
| SCHEMBL10305031 | 0.64 | OPRM1 (0.50) | DPP4DPP7GRIN2BNAMPT | |
| SCHEMBL31310231 | 0.64 | GRIN2D (0.37) | GRIN2B | |
| SCHEMBL17057261 | 0.62 | ITGB3 (0.41) | DPP4DPP7 | |
| SCHEMBL12763806 | 0.62 | POLB (0.46) | DPP4DPP7 | |
| SCHEMBL9946439 | 0.62 | OPRM1 (0.45) | DPP4DPP7GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794120-B1 | PEPTIDASE INHIBITORS | NUADA LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-7842707-B2 | Peptidase inhibitors | NUADA, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080234292-A1 | Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents | NUADA, LLC | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234292-A1 | Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents | DPP3, DPP4, DPP7 | DPP4 2/4885DPP7 3/4885BPTF 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.